Global Blood Therapeutics Inc (NASDAQ:GBT) – Equities researchers at Oppenheimer lifted their FY2017 earnings estimates for Global Blood Therapeutics in a research report issued on Thursday. Oppenheimer analyst M. Breidenbach now expects that the company will post earnings of ($2.46) per share for the year, up from their prior estimate of ($2.51). Oppenheimer has a “Buy” rating and a $79.00 price objective on the stock. Oppenheimer also issued estimates for Global Blood Therapeutics’ Q4 2017 earnings at ($0.65) EPS, Q1 2018 earnings at ($0.66) EPS, Q2 2018 earnings at ($0.69) EPS, Q3 2018 earnings at ($0.70) EPS, Q4 2018 earnings at ($0.72) EPS, FY2018 earnings at ($2.76) EPS, Q1 2019 earnings at ($0.75) EPS, Q2 2019 earnings at ($0.79) EPS, Q3 2019 earnings at ($0.82) EPS, Q4 2019 earnings at ($0.87) EPS, FY2019 earnings at ($3.22) EPS, FY2020 earnings at ($0.85) EPS and FY2021 earnings at $5.29 EPS.

Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings data on Thursday, November 2nd. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). During the same quarter in the prior year, the firm earned ($0.58) EPS.

Several other analysts have also issued reports on the stock. HC Wainwright set a $73.00 target price on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Thursday, January 11th. BidaskClub lowered shares of Global Blood Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 20th. Wedbush reiterated an “outperform” rating and issued a $73.00 target price on shares of Global Blood Therapeutics in a research report on Friday, December 15th. Needham & Company LLC lifted their target price on shares of Global Blood Therapeutics from $51.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, December 14th. Finally, Nomura lifted their target price on shares of Global Blood Therapeutics to $91.00 and gave the company a “buy” rating in a research report on Monday, December 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $62.07.

Global Blood Therapeutics (GBT) opened at $56.60 on Monday. Global Blood Therapeutics has a fifty-two week low of $14.70 and a fifty-two week high of $57.75.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Schwab Charles Investment Management Inc. raised its stake in Global Blood Therapeutics by 35.0% during the second quarter. Schwab Charles Investment Management Inc. now owns 149,634 shares of the company’s stock worth $4,093,000 after purchasing an additional 38,829 shares during the period. Rhumbline Advisers raised its stake in Global Blood Therapeutics by 118.5% during the second quarter. Rhumbline Advisers now owns 41,801 shares of the company’s stock worth $1,143,000 after purchasing an additional 22,670 shares during the period. SG Americas Securities LLC raised its stake in Global Blood Therapeutics by 93.9% during the second quarter. SG Americas Securities LLC now owns 8,288 shares of the company’s stock worth $227,000 after purchasing an additional 4,014 shares during the period. Bank of New York Mellon Corp raised its stake in Global Blood Therapeutics by 32.1% during the second quarter. Bank of New York Mellon Corp now owns 184,173 shares of the company’s stock worth $5,037,000 after purchasing an additional 44,784 shares during the period. Finally, Legal & General Group Plc raised its stake in Global Blood Therapeutics by 93.4% during the second quarter. Legal & General Group Plc now owns 9,315 shares of the company’s stock worth $256,000 after purchasing an additional 4,499 shares during the period. Hedge funds and other institutional investors own 85.72% of the company’s stock.

In other Global Blood Therapeutics news, major shareholder Perceptive Advisors Llc purchased 175,000 shares of the stock in a transaction that occurred on Tuesday, December 19th. The shares were purchased at an average cost of $38.00 per share, for a total transaction of $6,650,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Peter Radovich sold 15,000 shares of the business’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $50.00, for a total transaction of $750,000.00. Following the transaction, the insider now owns 17,684 shares in the company, valued at $884,200. The disclosure for this sale can be found here. Insiders have sold 100,500 shares of company stock worth $3,675,050 over the last 90 days. 5.30% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/16/fy2017-earnings-estimate-for-global-blood-therapeutics-inc-gbt-issued-by-oppenheimer.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Earnings History and Estimates for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Stock Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related stocks with our FREE daily email newsletter.